Christus Stehlin Foundation for Cancer Research

Robotic versus laparoscopic colectomy for deep infiltrative endometriosis of the bowel: a propensity-matched analysis of US-based hospitals

M A Abd Elhadi, Diego Z. Arellano, Jean-Paul Lefave, Eric M. Haas

us (code pays fourni par la source)

Voices of women with low-grade serous ovarian cancer: Results from a multinational survey

Charlotte C. Sun, Nicole Emma Andrews, Jane Ludemann, Elsa Larsen et autres

us, ca, au, gb, nz, fr (code pays fourni par la source)

Personalized multimodality therapy with immune checkpoint inhibitors, chemotherapy, and targeted treatment (ICTriplex) in advanced/refractory cancer.

Philip A. Salem, Khaled W. Jabboury, William G.B. McCallum, Randall A. Stenoien et autres

e14590 Background: Advanced/refractory malignancies are associated with poor prognosis and their treatment remains a major challenge. The combination of immune checkpoint inhibitors (ICI) and chemotherapy (CT) has been shown in some cancers to be superior to chemotherapy alone. In our treatment program …

us (code pays fourni par la source)

Personalized multimodality therapy (ICT) with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT), in advanced/refractory cancer.

Philip A. Salem, Khaled W. Jabboury, Thomas M. Wheeler, Randall A. Stenoien

e15150 Background: Therapy for advanced/refractory malignancies is associated with poor prognosis. The combination of ICI and CT has been shown in lung and several other cancers to be superior to CT alone. Since ICI, CT, and TT have a convergent efficacy with …

us (code pays fourni par la source)

Personalized multimodality therapy with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT) in advanced refractory cancer.

Philip A. Salem, Khaled W. Jabboury, Randall A. Stenoien, Thomas M. Wheeler et autres

e14254 Background: Therapy for advanced refractory malignancies remains a major challenge. As the combination of ICI and CT has been shown in some cancers to be superior to CT alone, and as ICI, CT, and TT have efficacy, but divergent toxicity; this …

us, it (code pays fourni par la source)

Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity

Dong Dong, Cheng‐Hui Hsiao, Beppino C. Giovanella, Yifei Wang et autres

Background and aim: We have synthesized a novel lactone-stabilized camptothecin (CPT) analog named CZ48 and demonstrated its potent anticancer effects via bioconversion to the active CPT in earlier studies. Herein, we aimed to develop, optimize and characterize CZ48 nanosuspensions, for a sustained …

cn, us (code pays fourni par la source)

Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats

Nur Özten Kandaş, Katherine Vega, Joachim G. Liehr, Xi Huang et autres

us (code pays fourni par la source)

The inhibitory effects of camptothecin (CPT) and its derivatives on the substrate uptakes mediated by human solute carrier transporters (SLCs)

Jian Zheng, Ting Chan, Ling Zhu, Xiufeng Yan et autres

1. Camptothecin (CPT) and its derivatives are potent candidate compounds in treating cancers. However, their clinical applications are largely restricted by severe toxicities. 2. The solute carrier transporters (SLCs), particularly the organic anion transporting polypeptides and organic anion/cation transporters (OATs/OCTs) are widely …

au, cn, us (code pays fourni par la source)

Abstract CT127: Can potential curability be reached in high risk/metastatic breast cancer patients with a treatment optimization strategy that includes a novel GNT (gemcitabine, vinorelbine, docetaxel) in front line combination chemotherapy

Khaled W. Jabboury, Lena Rogers, Krystal R. Sexton, Odelia Garcia

Abstract Aiming at improving the therapeutic outcome of sequential taxane and anthracycline front line chemotherapy in breast cancer, G and N were incorporated into the taxane arm; GNT x 4 courses (G 1800-2500mg/m2, N 20-30mg/m2, T 100mg/m2, I.V. on day 1. GNT …

us (code pays fourni par la source)

Abstract 4337: In vitro biotransformation of and inhibitory effects of CZ48 in human liver microsomes

Xing Liu, Albert DeJesus, Dana Vardeman, Zhisong Cao et autres

Abstract BACKGROUND AND PURPOSE CZ48 is a novel potent anticancer agent currently in a phase I clinical trial. The absorption of CZ48 in humans is approximately less than 10% based on the excretion ratio of the unchanged form in the feces following …

us (code pays fourni par la source)

A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.

Devalingam Mahalingam, Montaser F. Shaheen, John Sarantopoulos, Steven D. Weitman et autres

2578 Background: CZ48, the 20-O-propionate ester of camptothecin (CPT), is a prodrug of CPT first described by Cao et al. in 1998. The side-chain is enzymatically cleaved in tissues. This gives rise to CPT, a potent inhibitor of topoisomerase I. Methods: An …

us (code pays fourni par la source)

Enhanced Lactone Stability of CZ48 in Blood Correlates to its Lack of Toxicity in Mice

Xing Liu, Yang Wang, Zhisong Cao, Max Zhan et autres

PURPOSE: The aim of this study was to correlate the relationship between the pharmacokinetic behaviors and the toxicity of a new investigational anticancer agent CZ48, a C20-propionate ester of camptothecin (CPT) in mice. METHODS: In this study, the safety and pharmacokinetics of …

us (code pays fourni par la source)